J F Colombel

Summary

Affiliation: CHRU de Lille
Country: France

Publications

  1. ncbi [Inflammatory bowel diseases: a disease of the century]
    Jean Frederic Colombel
    Service d hépato gastro entérologie et Inserm EPI 01 14, Hopital Claude Huriez, 59037 Lille
    Rev Prat 55:941-2. 2005
  2. ncbi The CARD15 (also known as NOD2) gene in Crohn's disease: are there implications for current clinical practice?
    Jean Frederic Colombel
    Department of Hepato Gastroenterology, Hopital Claude Huriez, CHRU de Lille and Registre EPIMAD, Hopital Calmette, Lille, France
    Clin Gastroenterol Hepatol 1:5-9. 2003
  3. ncbi Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial
    Jean Frederic Colombel
    Department of Hepatogastroenterology, Hopital Claude Huriez, Centre Hospitalier Universitaire de Lille, Rue Michel Polonovski, 59037 Lille, France
    Gastroenterology 132:52-65. 2007
  4. ncbi Efficacy and safety of adalimumab for the treatment of Crohn's disease in adults
    Jean Frederic Colombel
    Hopital Huriez, Service d Hepatogastroenterologie, CHU Lille, rue Polonovski, 59037 Lille, Cedex, France
    Expert Rev Gastroenterol Hepatol 2:163-76. 2008
  5. ncbi Adalimumab for the treatment of fistulas in patients with Crohn's disease
    J F Colombel
    Hopital Claude Huriez, Centre Hospitalier Universitaire de Lille, Rue Michel Polonovski, Lille, France
    Gut 58:940-8. 2009
  6. ncbi Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease
    J F Colombel
    Gastroenterology Unit, Hopital Claude Huriez, Lille, France
    Gut 49:42-6. 2001
  7. ncbi Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial
    Jean Frederic Colombel
    Department of Hepatogastroenterology, Hopital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France
    Am J Gastroenterol 104:1170-9. 2009
  8. ncbi Adalimumab safety in global clinical trials of patients with Crohn's disease
    Jean Frederic Colombel
    Hopital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France
    Inflamm Bowel Dis 15:1308-19. 2009
  9. ncbi Natalizumab: a promising treatment for Crohn's disease
    Jean Frederic Colombel
    Hopital Huriez, Service d Hépato Gastro Entérologie Rue Polonovski 59037 Lille Cedex, France
    Expert Rev Clin Immunol 2:677-89. 2006
  10. ncbi Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy
    J F Colombel
    Service d Hepato Gastroenterologie, Hopital Huriez, CHRU Lille, France
    Gastroenterology 118:1025-30. 2000

Detail Information

Publications30

  1. ncbi [Inflammatory bowel diseases: a disease of the century]
    Jean Frederic Colombel
    Service d hépato gastro entérologie et Inserm EPI 01 14, Hopital Claude Huriez, 59037 Lille
    Rev Prat 55:941-2. 2005
  2. ncbi The CARD15 (also known as NOD2) gene in Crohn's disease: are there implications for current clinical practice?
    Jean Frederic Colombel
    Department of Hepato Gastroenterology, Hopital Claude Huriez, CHRU de Lille and Registre EPIMAD, Hopital Calmette, Lille, France
    Clin Gastroenterol Hepatol 1:5-9. 2003
  3. ncbi Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial
    Jean Frederic Colombel
    Department of Hepatogastroenterology, Hopital Claude Huriez, Centre Hospitalier Universitaire de Lille, Rue Michel Polonovski, 59037 Lille, France
    Gastroenterology 132:52-65. 2007
    ....
  4. ncbi Efficacy and safety of adalimumab for the treatment of Crohn's disease in adults
    Jean Frederic Colombel
    Hopital Huriez, Service d Hepatogastroenterologie, CHU Lille, rue Polonovski, 59037 Lille, Cedex, France
    Expert Rev Gastroenterol Hepatol 2:163-76. 2008
    ..This article reviews the efficacy and safety of adalimumab in the treatment of adult patients with CD and discusses the role of adalimumab in the current and future management of CD...
  5. ncbi Adalimumab for the treatment of fistulas in patients with Crohn's disease
    J F Colombel
    Hopital Claude Huriez, Centre Hospitalier Universitaire de Lille, Rue Michel Polonovski, Lille, France
    Gut 58:940-8. 2009
    ..To evaluate the efficacy of adalimumab in the healing of draining fistulas in patients with active Crohn's disease (CD)...
  6. ncbi Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease
    J F Colombel
    Gastroenterology Unit, Hopital Claude Huriez, Lille, France
    Gut 49:42-6. 2001
    ..We also assessed the effect of Tenovil in preventing endoscopic recurrence 12 weeks after surgery...
  7. ncbi Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial
    Jean Frederic Colombel
    Department of Hepatogastroenterology, Hopital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France
    Am J Gastroenterol 104:1170-9. 2009
    ....
  8. ncbi Adalimumab safety in global clinical trials of patients with Crohn's disease
    Jean Frederic Colombel
    Hopital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France
    Inflamm Bowel Dis 15:1308-19. 2009
    ....
  9. ncbi Natalizumab: a promising treatment for Crohn's disease
    Jean Frederic Colombel
    Hopital Huriez, Service d Hépato Gastro Entérologie Rue Polonovski 59037 Lille Cedex, France
    Expert Rev Clin Immunol 2:677-89. 2006
    ..This article reviews the properties of natalizumab and addresses its potential benefits and risks in the treatment of CD...
  10. ncbi Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy
    J F Colombel
    Service d Hepato Gastroenterologie, Hopital Huriez, CHRU Lille, France
    Gastroenterology 118:1025-30. 2000
    ..We investigated the distribution of mutant alleles associated with TPMT deficiency in patients with CD and myelosuppression during azathioprine/6-mercaptopurine therapy...
  11. ncbi Infliximab, azathioprine, or combination therapy for Crohn's disease
    Jean Frederic Colombel
    Hôpital Claude Huriez and Centre d Investigation Clinique, Centre Hospitalier Universitaire de Lille, Universite Lille Nord de France, Lille, France
    N Engl J Med 362:1383-95. 2010
    ..The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for Crohn's disease are unknown...
  12. ncbi Low ileal interleukin 10 concentrations are predictive of endoscopic recurrence in patients with Crohn's disease
    B Meresse
    , CHU Lille, France
    Gut 50:25-8. 2002
    ..CONCLUSION: Low ileal IL-10 mRNA concentration is a good marker of endoscopic recurrence in Crohn's disease but the distribution of IL-10.G haplotypes cannot predict the postoperative evolution of the disease...
  13. ncbi Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease
    A Cortot
    Service de Gastroenterologie, Hopital Claude Huriez, Lille, France
    Gut 48:186-90. 2001
    ..Steroid dependent patients with Crohn's disease are at high risk of developing glucocorticosteroid induced side effects...
  14. ncbi CD28+ intraepithelial lymphocytes with long telomeres are recruited within the inflamed ileal mucosa in Crohn disease
    B Meresse
    Service d'Immunologie, EA 2686, Lille, France
    Hum Immunol 62:694-700. 2001
    ..Such perturbation of the IEL population within the ileal mucosa could contribute to the inflammation in Crohn disease...
  15. ncbi Eosinophilic gastroenteritis: ultrastructural evidence for a selective release of eosinophil major basic protein
    G Torpier
    Unité Mixte INSERM U 167 CNRS 624, Institut Pasteur, Lille, France
    Clin Exp Immunol 74:404-8. 1988
    ..The diffusion of one granule protein from the granules to the exterior of the cells favours the view of a selective release of eosinophil mediators...
  16. ncbi Parallel interleukin 5 synthesis by eosinophils in duodenal and skin lesions of a patient with dermatitis herpetiformis
    P Desreumaux
    Clinique des Maladies de l Appareil Digestif, Hopital Claude Huriez, Centre Hospitalier Regional Universitaire CHRU, Lille, France
    Gut 37:132-5. 1995
    ..It is suggested that duodenal and cutaneous eosinophils can synthesise IL5 and then participate in small bowel and skin lesions...
  17. ncbi Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine
    G Vernier Massouille
    Department of Hepato Gastroenterology, Hopital Claude Huriez, CH et U de Lille, France
    Gut 56:1404-9. 2007
    ....
  18. ncbi Early vascular changes in Crohn's disease: an endoscopic fluorescence study
    V Maunoury
    Dept of Gastroenterology, University Hospital, Lille, France
    Endoscopy 32:700-5. 2000
    ..The aim of this study was use fluorescence endoscopy to evaluate the mucosal microcirculation of the neoterminal ileum in relation to endoscopic recurrence in patients who had undergone ileocolonic resection for Crohn's disease...
  19. ncbi [Desensitisation to infliximab in patients with Crohn's disease]
    J Lelong
    Service de Pneumo-Allergologie, Clinique des Maladies Respiratoires, , CHRU, Lille, France
    Rev Mal Respir 22:239-46. 2005
    ..The mechanism of desensitisation remains presently unknown. It is not yet possible to say if desensitization will be effective in preventing delayed reactions...
  20. ncbi Pre-operative management is associated with low rate of post-operative morbidity in penetrating Crohn's disease
    P Zerbib
    Department of Digestive Surgery and Transplantation, Univ Lille Nord de France, CHU Lille, France
    Aliment Pharmacol Ther 32:459-65. 2010
    ..Ileocaecal resection for penetrating Crohn's disease is still challenging with a high rate of post-operative morbidity and faecal diversion...
  21. ncbi Mucin gene expression in intestinal epithelial cells in Crohn's disease
    M P Buisine
    Unité Inserm no 377, Lille, France
    Gut 49:544-51. 2001
    ..Crohn's disease (CD) is a chronic relapsing inflammatory bowel disease of unknown origin. It is characterised by chronic mucosal ulcerations which affect any part of the intestine but most commonly are found in the ileum and proximal colon...
  22. ncbi [Infliximab therapy for Crohn's disease anoperineal lesions]
    A Ouraghi
    , CHU, Lille, France
    Gastroenterol Clin Biol 25:949-56. 2001
    ..CONCLUSION: Remicade is rapidly effective and well tolerated in anoperineal Crohn's lesions, but the high relapse rate stresses the need for long term therapeutic strategies in these patients...
  23. ncbi Inflammation increases sufentanil requirements during surgery for inflammatory bowel diseases
    A Guidat
    Hopital Claude Huriez, Département d Anesthésie Réanimation 2, Lille, France
    Eur J Anaesthesiol 20:957-62. 2003
    ..Sufentanil requirements were assessed during surgery...
  24. ncbi Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies
    P Desreumaux
    Equipe Propre Institut National de la Sante et de la Recherche Medicale 0114 sur la Physiopathologie des Maladies Inflammatoires Intestinales, CHU Lille 59037, France
    J Exp Med 193:827-38. 2001
    ....
  25. ncbi Opposite evolution in incidence of Crohn's disease and ulcerative colitis in Northern France (1988-1999)
    F Molinie
    Registre des Maladies Inflammatoires Chroniques de l Intestin EPIMAD, Service d Epidémiologie et de Santé Publique, Hopital Calmette, CHR and U de Lille, 59037 Lille Cedex, France
    Gut 53:843-8. 2004
    ..Northern France was characterised by a high incidence of Crohn's disease (CD) and a low incidence of ulcerative colitis (UC) according to the first inquiry undertaken in the late 1980s...
  26. ncbi Health-related quality of life in Crohn's disease: a prospective longitudinal study in 231 patients
    F Blondel-Kucharski
    , CHU, Lille, France
    Am J Gastroenterol 96:2915-20. 2001
    ..CONCLUSION: Patients' QoL is impaired by CD and is underestimated by doctors. Tobacco, hospitalization, and use of corticoids have a negative impact on QoL. Conversely, the use of immunosuppressors is associated with a better QoL...
  27. ncbi Qualitative study of fecal alpha 1-proteinase inhibitor in normal subjects and patients with Crohn's disease
    C Mizon
    Laboratoire de Biochimie, , Lille, France
    Clin Chem 34:2268-70. 1988
    ..In contrast, alpha 1 PI of Mr 51,000 was detected in fecal extracts from eight patients with active Crohn's disease (CDAI = 287, SEM 39). We conclude that fecal alpha 1 PI can be considered a marker of intestinal disease activity...
  28. ncbi Antibodies against glucan, chitin, and Saccharomyces cerevisiae mannan as new biomarkers of Candida albicans infection that complement tests based on C. albicans mannan
    B Sendid
    INSERM U799, Universite Lille 2, Lille, France
    Clin Vaccine Immunol 15:1868-77. 2008
    ..Future trials are necessary to assess the value of these tests in multiparametric analysis, as well as their pathophysiological relevance...
  29. ncbi Simple gas chromatography analysis of faecal butyrate: application to patients at risk of pouchitis
    G Renom
    Laboratoire de Biochimie, Hopital Claude Huriez, Centre Hospitalier Regional Universitaire, Lille, France
    Clin Chem Lab Med 39:15-9. 2001
    ..We also observed a noticeable reduction in the concentration of butyrate in patients who went on to develop a pouchitis...
  30. ncbi Alpha-chain disease: analysis of alpha-chain protein and secretory component in jejunal fluid
    D Lucidarme
    Laboratoire d Explorations Fonctionelles Digestives, Centre Hospitalier Regional Universitaire, Lille, France
    Gastroenterology 104:278-85. 1993
    ..This was studied in a 23-year-old Mauritanian man in whom alpha-chain disease was diagnosed localized to the duodenum and jejunum, nasopharynx, and bone marrow...